Literature DB >> 8006122

Craniofacial abnormalities in animal models of mucopolysaccharidoses I, VI, and VII.

O Sheridan1, J Wortman, C Harvey, J Hayden, M Haskins.   

Abstract

The genetic mucopolysaccharidoses (MPS) are a family of lysosomal storage diseases resulting from the partial catabolism of several glycosaminoglycans (GAGs). Depending on the particular enzyme deficient in activity, the MPS syndromes are defined into groups MPS I through VII, with several subgroups for a total of 10 disorders. In humans, clinical features include dysostosis multiplex, hepatosplenomegaly, hypertelorism, macroglossia, hypoplastic and irregularly shaped teeth, hyperplastic lips and gingiva, facial dysmorphia, corneal clouding, and mental retardation. MPS I (alpha-L-iduronidase deficiency) and VI (arylsulfatase B deficiency) have been described in cats, MPS VII (beta-glucuronidase deficiency) in dogs. Biochemically, these syndromes appear the same as their human counterparts and have similar clinical characteristics. All are inherited as autosomal recessive traits. The purpose of this study was to analyze the craniofacial aspects of these diseases in the animal models and compare these data with descriptions of the human syndromes. A total of 28 live animals were examined. Thirty-one skulls prepared from postmortem specimens were measured directly and radiographed. Controls were closely related family members of the same sex and similar age without the disease, clinically or biochemically. The data indicated that, as in the human syndromes, each is distinct, and the skull bones most severely affected are those of endochondral origin.

Entities:  

Mesh:

Year:  1994        PMID: 8006122

Source DB:  PubMed          Journal:  J Craniofac Genet Dev Biol        ISSN: 0270-4145


  5 in total

1.  Chondroitin sulfate and growth factor signaling in the skeleton: Possible links to MPS VI.

Authors:  Tamara Alliston
Journal:  J Pediatr Rehabil Med       Date:  2010

Review 2.  A review of gene therapy in canine and feline models of lysosomal storage disorders.

Authors:  Allison M Bradbury; Brittney L Gurda; Margret L Casal; Katherine P Ponder; Charles H Vite; Mark E Haskins
Journal:  Hum Gene Ther Clin Dev       Date:  2015-02-11       Impact factor: 5.032

3.  Bone marrow transplantation for feline mucopolysaccharidosis I.

Authors:  N Matthew Ellinwood; Marie-Anne Colle; Margaret A Weil; Margret L Casal; Charles H Vite; Staci Wiemelt; Christopher W Hasson; Thomas M O'Malley; Xingxuan He; Ulana Prociuk; Lucie Verot; John R Melniczek; Anne Lannon; Gustavo D Aguirre; Van W Knox; Sydney M Evans; Marie T Vanier; Edward H Schuchman; Steven U Walkley; Mark E Haskins
Journal:  Mol Genet Metab       Date:  2007-05-07       Impact factor: 4.797

4.  Growth plate pathology in feline mucopolysaccharidosis VI.

Authors:  S Abreu; J Hayden; P Berthold; I M Shapiro; S Decker; D Patterson; M Haskins
Journal:  Calcif Tissue Int       Date:  1995-09       Impact factor: 4.333

5.  Mucopolysaccharidosis VI in cats - clarification regarding genetic testing.

Authors:  Leslie A Lyons; Robert A Grahn; Francesca Genova; Michela Beccaglia; John J Hopwood; Maria Longeri
Journal:  BMC Vet Res       Date:  2016-07-02       Impact factor: 2.741

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.